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Narcolepsy, characterized by excessive daytime sleepiness, is associated with dysfunction of the hypothalamic hypocretin/orexin (Hcrt)
system, either due to extensive loss of Hcrt cells (Type 1, NT1) or hypothesized Hcrt signaling impairment (Type 2, NT2). Accordingly,
efforts to recapitulate narcolepsy-like symptoms in mice have involved ablating these cells or interrupting Hcrt signaling. Here, we
describe orexin/Arch mice, in which a modified archaerhodopsin-3 gene was inserted downstream of the prepro-orexin promoter, result-
ing in expression of the yellow light-sensitive Arch-3 proton pump specifically within Hcrt neurons. Histological examination along with
ex vivo and in vivo electrophysiological recordings of male and female orexin/Arch mice demonstrated silencing of Hcrt neurons when
these cells were photoilluminated. However, high expression of the Arch transgene affected cellular and physiological parameters inde-
pendent of photoillumination. The excitability of Hcrt neurons was reduced, and both circadian and metabolic parameters were per-
turbed in a subset of orexin/Arch mice that exhibited high levels of Arch expression. Orexin/Arch mice also had increased REM sleep under
baseline conditions but did not exhibit cataplexy, a sudden loss of muscle tone during wakefulness characteristic of NT1. These aberra-
tions resembled some aspects of mouse models with Hcrt neuron ablation, yet the number of Hcrt neurons in orexin/Arch mice was not
reduced. Thus, orexin/Arch mice may be useful to investigate Hcrt system dysfunction when these neurons are intact, as is thought to
occur in narcolepsy without cataplexy (NT2). These results also demonstrate the utility of extended phenotypic screening of transgenic
models when specific neural circuits have been manipulated.
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Introduction
The hypocretin/orexin (Hcrt) system is a hypothalamic neuro-
peptide system that is involved in behavioral arousal, metabo-
lism, reward, stress, and neuroendocrine function (Sakurai, 2007;
Mahler et al., 2014; Li et al., 2017). Defects in this system, either
presynaptically or postsynaptically, result in Type 1 narcolepsy
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Significance Statement
Optogenetics has become an invaluable tool for functional dissection of neural circuitry. While opsin expression is often achieved
by viral injection, stably integrated transgenes offer some practical advantages. Here, we demonstrate successful transgenic
expression of an inhibitory opsin in hypocretin/orexin neurons, which are thought to promote or maintain wakefulness. Both brief
and prolonged illumination resulted in inhibition of these neurons and induced sleep. However, even in the absence of illumina-
tion, these cells exhibited altered electrical characteristics, particularly when transgene expression was high. These aberrant
properties affected metabolism and sleep, resulting in a phenotype reminiscent of the narcolepsy Type 2, a sleep disorder for which
no good animal model currently exists.
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(NT1) in humans and animals (Scammell, 2015; Black et al.,
2017a; Bassetti et al., 2019; Szabo et al., 2019). Since the primary
symptoms of NT1 are excessive daytime sleepiness (EDS) and
cataplexy, the Hcrt system is widely acknowledged to promote
wakefulness and maintain muscle tone. The Hcrt system also has
a role in energy metabolism and homeostasis (Hara et al., 2001;
Yamanaka et al., 2003b; Funato et al., 2009). In support of this
concept, the phenotype of narcoleptic mice (Hara et al., 2001;
Inutsuka et al., 2014) replicates the increased body mass index
reported in narcoleptic patients (Schuld et al., 2000, 2002).
Although afferent control of Hcrt neurons is relatively well
characterized (Sakurai et al., 2005; Yoshida et al., 2006; Sakurai,
2007), and the efferent projections of the Hcrt neurons have been
known for some time (Peyron et al., 1998; Date et al., 1999),
relatively little progress in understanding the functionality of
Hcrt efferents was made until the advent of optogenetics. An
optogenetic study of the Hcrt system was the first in vivo imple-
mentation of this technology (Adamantidis et al., 2007), and sub-
sequent optogenetic studies have also “shed light” on Hcrt
function. For example, the short latency awakenings from sleep-
evoked by channelrhodopsin-2 (ChR2)-mediated Hcrt neuron
photoactivation (Adamantidis et al., 2007) have been shown to be
sensitive to the sleep pressure induced by sleep deprivation (SD)
(Carter et al., 2009). Photoinhibition of locus ceruleus (LC) neu-
rons blocks these Hcrt-mediated sleep-to-wake transitions
(Carter et al., 2012), implying that an Hcrt¡ LC pathway may be
one circuit underlying the cortical activation that occurs during
wakefulness.
In contrast to neural activation by ChR2, optogenetic neuro-
nal silencing has been achieved by expression of the orange light-
sensitive protein halorhodopsin, which opens a chloride channel
(Han and Boyden, 2007; Zhang et al., 2007), and the yellow light-
sensitive proteins archaerhodopsin-3 (Arch) or ArchT, both of
which activate a proton pump (Chow et al., 2010; Han et al.,
2011). Using these tools, photoinhibition of Hcrt neurons with
halorhodopsin (Tsunematsu et al., 2011) or ArchT (Tsunematsu
et al., 2013) has been shown to increase time spent in slow-wave
sleep during the active phase. In vitro optogenetics combined
with pharmacology has also revealed the relative contributions of
glutamate- versus Hcrt-mediated excitation of the tuberomam-
millary neurons (Schöne et al., 2012) and provided evidence for
corelease of these neurotransmitters onto Hcrt cells (Schöne et
al., 2014). Similar approaches have demonstrated that Hcrt neu-
rons can inhibit melanin-concentrating hormone cells (Apergis-
Schoute et al., 2015).
In the present study, we characterize a new transgenic mouse
line, orexin/Arch mice, to further understand the Hcrt/orexin sys-
tem. During the course of in vitro electrophysiological experi-
ments, a surprising degree of variability in the response of orexin/
Arch-expressing cells to stimulation was evident. Further analysis
revealed that high levels of Arch transgene expression negatively
affected Hcrt neuronal excitability in the absence of any illumi-
nation and significantly altered body weight and REM sleep.
Thus, orexin/Arch mice may be a useful tool for study of energy
metabolism as well as sleep–wake control, and these data under-
score the need for detailed phenotypic screening of transgenic
mouse models when specific neural circuits are targeted.
Materials and Methods
Animals
All experimental procedures conducted at SRI International were ap-
proved by the Institutional Animal Care and Use Committee at SRI
International and were conducted in accordance with the principles set
forth in the Guide for Care and Use of Laboratory Animals, National
Research Council. All experimental procedures conducted in Japan in-
volving animals were approved by the National Institute for Physiologi-
cal Sciences Animal Care and Use Committee and were in accordance
with National Institutes of Health guidelines. All efforts were made to
minimize animal suffering or discomfort and to reduce the number of
animals used. All rodents were maintained under 12 h light/12 h dark
(LD) conditions at 22  2°C and 50  25% relative humidity with food
and water ad libitum.
Generation of orexin/Arch mice
The transgenic construct was made by substituting the nLacZ gene (SalI-
BamHI fragment) of the orexin/nLacZ construct with the 1.5 kb Arch
fragment (Han and Boyden, 2007; Chow et al., 2010), which is expressed
as a fusion protein with eGFP. The transgene was excised and microin-
jected into pronuclei of fertilized mouse eggs (BDF1 mice) to generate
transgenic founders. Founders were bred with BDF1 mice to produce
stable orexin/Arch transgenic lines. A total of 12 transgene-positive
founders were obtained. Analysis of the N1 generation demonstrated
that only one line (line D3) showed strong expression of Arch, so line D3
was used for subsequent experiments. The mice studied in Japan and at
SRI International were derived from same founders and are available
from the RIKEN BioResource Center (RBRC05845). At SRI Interna-
tional, orexin/Arch mice were backcrossed with C57BL/6J mice.
Genotyping
DNA was extracted and isolated from tail snips. Quantitative PCR
(qPCR) was used to determine transgene insertion and relative abun-
dance. The 20 l qPCR contained 4 l of target and internal positive
control primers, 5 l nuclease-free water, 1 l of DNA sample (100
ng), and 10 l of KAPA SYBR FAST qPCR master mix. At SRI Interna-
tional, qPCR analysis used a 7300 Real-Time PCR System (Applied Bio-
sciences) running the following program: 95°C for 10 min, 42 cycles of
95°C for 15 s, and 60°C for 1 min. At Nagoya University, qPCR analysis
was conducted using the StepOne Real-Time PCR System (Applied Bio-
sciences) using the following program: 95°C for 30 s, 40 cycles at 95°C for
3 s, and 60°C for 30 s. The ramp of each machine was set to the default.
The primers chosen provided the best melting curves. Target primer
sequences were as follows: hHCRT1prom1 forward, CCGGGAAAGGA
GATGTCTGT, hHCRTprom1 reverse, CGCCACCTCAGAGCACTA
TA; internal positive control promoters: mTfrc forward, TGGGCAC
TAGATTGGATACCT, mTfrc reverse, GTCCAGGTTCAATTCAAC
GTCA (all from Midland Certified Reagent). Ct values were assessed
relative to an original founder mouse with high Arch transgene expres-
sion (aHE). Mice with qPCR values 0.9 were classified as aHE, and
those 0.9 were classified as low Arch transgene expressers (aLE).
Immunohistochemistry and cell counting
Tissue preparation. Male and female orexin/Arch transgenic mice that
were killed for histological examination received a terminal injection of
SomnaSol (Henry Schein) before transcardial perfusion with PBS con-
taining heparin followed by 4% PFA. After removal of the brain, the
tissue was cryoprotected (30% sucrose, 0.1 M PBS) and cut into 6 series of
30 m thick coronal sections in preparation for immunohistochemical
processing.
Immunostaining. For double-fluorescent immunohistochemistry of
orexin-containing neurons, guinea pig anti-orexin antiserum (1:800,
Vector Laboratories) and AlexaFluor-594-labeled goat anti-guinea pig
IgG (1:800, Invitrogen) were used to detect Hcrt/orexin neurons in com-
bination with rabbit anti-GFP antiserum (1:1000, Invitrogen) and
AlexaFluor-488-labeled anti-rabbit IgG (1:800, Invitrogen) to detect the
Arch-eGFP transgene in Hcrt neurons. For triple-fluorescent immuno-
histochemistry, goat anti-orexin-A (1:3000, Santa Cruz Biotechnology,
catalog #sc-8070; RRID:AB_653610) and goat anti-orexin-B (1:3000,
Santa Cruz Biotechnology, catalog #sc-8071; RRID:AB_653612) anti-
bodies were processed sequentially to prevent secondary signal cross-
reactivity; the Arch transgene was then detected with chicken anti-GFP
antiserum (1:1000, Abcam, catalog #ab13970; RRID:AB_300798) and
AlexaFluor-488 affiniPure donkey anti-chicken IgG (1:500, Jackson Im-
munoResearch Laboratories). The orexin-A antisera was detected with
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AlexaFluor-594 affiniPure donkey anti-goat IgG (1:500, Jackson Immu-
noResearch Laboratories), whereas the orexin-B antisera was detected
with AMCA-streptavidin (1:500, Jackson ImmunoResearch Laborato-
ries) after incubation with Affinipure donkey anti-goat IgG (1:1000,
Jackson ImmunoResearch Laboratories).
Innervation of downstream targets from Hcrt/orexin neurons. To deter-
mine whether the Arch transgene was expressed within orexin-con-
taining fibers, we detected Arch-eGFP with chicken anti-GFP antiserum
(1:1000, Abcam, catalog #ab13970; RRID:AB_300798) before secondary
incubation of Affinipure donkey anti-chicken IgG (1:1000, Jackson Im-
munoResearch Laboratories). Arch-eGFP was detected with nickel-
enhanced 3,3 diaminobenzidine tetrahydrochloride (nDAB; 30 s;
SK4100, Vector Laboratories).
Determination of Hcrt/orexin neuron size. Goat anti-orexin-A (1:3000,
Santa Cruz Biotechnology, catalog #sc-8070; RRID:AB_653610) and
goat anti-orexin-B (1:3000, Santa Cruz Biotechnology, catalog #sc-8071;
RRID:AB_653612) antibodies were combined and detected with Affini-
pure donkey anti-goat IgG (1:1000, Jackson ImmunoResearch Labora-
tories) and 3,3 diaminobenzidine tetrahydrochloride (DAB; 2 min;
SK4100, Vector Laboratories). Sections were mounted on Superfrost
slides and coverslipped. Using a CTR 5000 microscope (Leica Microsys-
tems), images of the lateral hypothalamic area (LHA) containing orexin-
positive neurons were captured for processing in ImageJ.
Colocalization cell counts. Bilateral counts from 3 to 6 sections were
taken from each mouse. All sections were mounted on Superfrost slides,
coverslipped, and visualized on a CTR 5000 microscope (Leica Micro-
systems). Analyses were conducted blind to genotype and condition.
Transduction efficiency of the Arch-eGFP transgene within the orexin-
containing neurons was calculated by counting the number of Arch-
eGFP /orexin-immunoreactive (IR)  cells, and the total number of
orexin-IR  cell bodies and then calculating the percentage of double-
labeled cells relative to the total number of orexin-expressing neurons.
The same process was applied to calculate c-FOS activation within the
orexin-containing neurons. Arch transduction specificity was calculated
as the proportion of GFP-IR  cells that coexpressed orexin-IR  relative
to the total number of GFP-IR  cells. The region measured included all
orexin-IR  cell bodies within the tuberal hypothalamus in the sections
used for immunohistochemical quantification (bregma: 1.30 mm to
1.70 mm) (Franklin and Paxinos, 2008).
The same analyses were performed to calculate Arch transgene expres-
sion within either orexin-A-IR  or orexin-B-IR  neurons. We found no
differences in Arch transgene expression between medial and lateral as-
pects of the tuberal hypothalamus, nor between orexin-A-IR  or orexin-
B-IR  neurons. Therefore, we combined orexin antisera for subsequent
analysis and refer to the orexin/Arch neurons as located within the LHA.
Grouped data are expressed as mean  SEM.
Photoinhibition of Hcrt/orexin neurons in vivo. Arch can be activated by
application of either yellow or green light to evoke neuronal silencing
(Chow et al., 2010). To measure of the efficacy of Arch-mediated photo-
inhibition of Hcrt cells, green light illumination (550  15 nm) was
delivered into the hypothalamus of WT (n  11) and orexin/Arch (n 
12) mice at ZT12 through the bilaterally implanted optical fibers (see In
vivo optogenetics and tethered EEG recording) continuously for 1 h. At
ZT13, mice were killed for histology. Brain sections were processed for
orexin-IR (guinea pig anti-orexin antiserum as described above) and
rabbit anti-c-Fos antiserum (1:6000; AB5, Calbiochem). Affinipure don-
key anti-guinea pig IgG (Vector Laboratories) and Affinipure donkey
anti-rabbit IgG (Vector Laboratories) were used as secondary antibodies.
Orexin-IR was detected with DAB (2 min; SK4100, Vector Laboratories);
c-FOS was detected with nDAB (10 min; SK4100, Vector Laboratories).
Activation of Hcrt/orexin neurons in the chocolate-cataplexy assay
(CCA). Mice implanted with EEG/EMG telemetry devices (see below)
were permitted access to chocolate (1  Hershey’s kiss) from ZT12 to
ZT16. At ZT16, mice were killed for histological examination (WT, n 
8; aLE, n  10; aHE, n  5; ATAX, n  5). Brain sections were processed
for orexin-IR (combined anti-orexin-A and anti-orexin B antibodies as
described above) and rabbit anti-c-FOS antiserum (1:2000; sc-52, Santa
Cruz Biotechnology). Secondary antisera used were Affinipure donkey
anti-goat IgG (1:1000, Jackson ImmunoResearch Laboratories) and Af-
finipure donkey anti-rabbit IgG (1:1000, Jackson ImmunoResearch Lab-
oratories). Orexin-IR was detected with DAB (2 min; SK4100, Vector
Laboratories), and c-FOS was detected with nDAB (10 min; SK4100,
Vector Laboratories).
Ex vivo electrophysiology
Recording of Hcrt/orexin neurons in vitro. Coronal brain slices (250 m)
of the tuberal hypothalamus were prepared from juvenile (P14-P27) or
adult (	8 weeks) male and female orexin/Arch and orexin/eGFP (Ya-
manaka et al., 2003a,b) mice in ice-cold, oxygenated (95% O2, 5% CO2)
sucrose-based aCSF containing the following (in mM): 250 sucrose, 2.5
KCl, 1.24 NaH2PO4, 10 MgCl2, 10 glucose, 26 NaHCO3, 0.5 CaCl2 (305
mOsm/L). Slices were incubated in aCSF containing the following (in
mM): 124 NaCl, 2.5 KCl, 1.24 NaH2PO4, 1.3 MgCl2, 10 glucose, 26
NaHCO3, 2.5 CaCl2 (300 mOsm/L) at 37°C for 15 min. Thereafter, slices
were maintained and recorded at 22°C with aCSF flow rate of 
1.5
ml/min. For voltage- and current-clamp recordings, the pipette solution
contained the following (in mM): 130 K-gluconate, 2 KCl, 3 MgCl2, 2
MgATP, 0.2 Na2GTP, 10 HEPES, 0.2 EGTA (290 mOsm/L, pH 7.3). To
measure sIPSC activity, the pipette solution contained the following (in
mM): 145 CsCl, 10 HEPES, 1.1 EGTA, 0.3 CaCl2, 1 MgCl2H2O, 0.5
Na2GTP (290 mOsm/L, pH 7.3 with CsOH). All recordings were ac-
quired with a MultiClamp 700A amplifier, Digidata 1322A digitizer in-
terface and pClamp 9 software (Molecular Devices). Voltage-clamp data
were sampled at 7 kHz and filtered at 3 kHz; current-clamp data were
sampled at 20 –25 kHz and filtered at 10 kHz. Changes in input resistance
(Rin) were monitored across the experiments by injecting hyperpolariz-
ing steps (20 or 40 pA) and periodically switching from voltage-
clamp mode to recording in current-clamp mode. Voltage-clamp
recordings were then concatenated to remove breaks.
For current-clamp recordings, Hcrt/orexin neurons were recorded at
their resting membrane potential (RMP). For voltage-clamp recordings,
Vh was 60 mV. Series resistance varied from 10 to 60 M and was
monitored during voltage-clamp recordings. Any neurons deviating
	10% in series resistance over time were excluded from analysis; the
bridge balance was maintained and monitored during current-clamp
recordings. Membrane potential measurements were not corrected for
the theoretical liquid junction potential of 15 mV (K-Glu intracellular)
or 5 mV (CsCl intracellular) between pipette solution and bath solution.
The reference electrode was a Ag/AgCl  pellet.
Activation of Arch proton pump ex vivo. Whole-field illumination (40
objective) of yellow light (550  15 nm) was generated by a SPECTRA III
light engine (Lumencor).
In vivo optogenetics and tethered EEG recording
Optical fiber placement with EEG. Fifteen-week-old male orexin/Arch
transgenic mice and their WT littermates were anesthetized with isoflu-
rane using a vaporizer for small animals (400, Bio Research Center) and
positioned in a stereotaxic frame (David Kopf Instruments). Plastic op-
tical fibers (0.5 mm diameter; Eska, Mitsubishi Rayon) were bilaterally
implanted 
1 mm above the LHA (1.2 mm posterior, 1 mm lateral from
Bregma, 3.5 mm depth from brain surface). Electrodes for EEG and EMG
were implanted on the skull and neck muscles, respectively, and were
attached to the skull using dental cement (GC). The mice were then
housed separately for a recovery period of at least 7 d before recording.
Continuous EEG and EMG recordings were performed through a slip
ring (Air Precision) designed so that the movement of the mouse was
unrestricted. EEG and EMG signals were amplified (AB-610J, Nihon
Koden), filtered (EEG, 1.5–30 Hz; EMG, 15–300 Hz), digitized at a sam-
pling rate of 128 Hz, and recorded using SleepSign software version 3
(Kissei Comtec). Green light (550  15 nm) was generated by the SPEC-
TRA III light engine (Lumencor) and applied through the plastic optical
fibers. An optical swivel (COME2, Lucir) was used for unrestricted in
vivo photoillumination. Green light power intensity at the tip of the
plastic fiber optics (0.5 mm diameter) was measured with a power meter
to be 0.46 mW/mm 2 (VEGA, Ophir Optronics). The animal’s behavior
was monitored through a CCD video camera and recorded on a com-
puter synchronized with EEG and EMG recordings using the SleepSign
video option (Kissei Comtec).
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In vivo validation of orexin/Arch transgenic mice. Three experiments
were performed to assess the functionality of Arch in response to green
light stimulation: (1) Green illumination was applied for a 1 min dura-
tion when mice were awake during both the inactive (ZT5-ZT11) and
active phases (ZT13-ZT15). Each mouse received 1–3 illuminations, with
a minimum intervening period of 4 d between photic stimulations. (2) If
slow-wave activity was recorded within 30 s of initiation of photic stim-
ulation, mice received tactile stimulation from an artist’s brush to deter-
mine whether they could be aroused from the optogenetically induced
sleep. (3) One hour continuous photoillumination was applied 6 times
across the day/night cycle: at ZT12, ZT16, ZT20, ZT0, ZT4, and ZT8.
In vivo phenotyping of orexin/Arch transgenic mice
Implantation of EEG/EMG telemetry devices for basal sleep–wake analyses.
Male orexin/Arch mice, orexin/Ataxin-3 (ATAX ) mice (Hara et al., 2001),
and WT littermates (	10 weeks of age) were implanted with bioteleme-
try transmitters (F20-EET; Data Sciences International) for chronic re-
cording of EEG, EMG, core body temperature (Tb), and gross motor
activity as previously described (Black et al., 2013, 2014, 2017b). Male
mice implanted with telemeters were of the same age range (WT: 3.27 
0.27 months, n  9; ATAX: 3.46  0.37 months, n  6; aLE: 2.86  0.18
months, n  9; aHE: 3.20  0.19 months, n  8; one-way ANOVA,
F(3,28)  1.14, p  0.35) and similar body weight at the beginning of the
study (WT: 32.11  1.60 g; ATAX: 31.83  1.49 g, n  6; aLE: 32.00 
1.46 g; aHE: 37.00  1.85 g; one-way ANOVA, F(3,28)  2.35, p  0.09).
Following a postsurgical recovery period, mice were singly housed with
access to running wheels.
SD procedures. For experiments related to sleep homeostasis, the ref-
erence time was lights-on (ZT0) when sleep pressure is high. To deter-
mine whether there were any differences in homeostatic sleep regulation
across the 4 strains, mice were kept awake/sleep deprived for 4 h begin-
ning at ZT0. SD was achieved by tapping the home cage and, when
necessary, stroking the vibrissae or fur with an artist’s brush to keep mice
awake for the 4 h duration. To be included in the final analysis, mice must
have been awake 	80% of the SD period.
Murine multiple sleep latency (mMSLT) test. To objectively measure
sleepiness, we performed a variation of the mMSLT (Veasey et al., 2004)
as previously described (Morairty et al., 2013). Starting 3 h into the light
phase (ZT3), mice were subjected to five 20 min sessions of forced wak-
ing, each followed by a 20 min nap opportunity within a continuous 200
min time interval. The latencies to the onset of NREM and REM sleep as
well as the percentage of time spent in each vigilance state were deter-
mined for each nap opportunity. To be included in the final analyses,
mice must have been awake 	80% of each forced waking period.
Vigilance state and cataplexy assessments. As described below and in
our previous publications (Black et al., 2013, 2014, 2017b; Schwartz et al.,
2017), EEG and EMG data were classified in 10 s epochs as wakefulness,
NREM, REM, or cataplexy. Criteria for cataplexy were 10 s of EMG
atonia, theta-dominated EEG, and video-confirmed behavioral immo-
bility preceded by 40 s of wake (Scammell et al., 2009). All mice had
access to a wheel. To facilitate the occurrence of cataplexy, we used the
CCA in which mice were given 1  Hershey’s kiss at ZT12 for a 24 h
period (Oishi et al., 2013). Chow and chocolate consumption was mea-
sured during the assay to determine whether there was a taste preference
between mouse strains. Two weeks before the CCA, all mice were given
1 g of a Hershey’s kiss to acclimate mice to the smell and presentation of
the chocolate. At the end of the basal sleep–wake phenotyping experi-
ments, mice (WT, n  8; aLE, n  10; aHE, n  5; ATAX, n  5) were
given 1  Hershey’s kiss at ZT12 and killed for histology at ZT16.
Circadian assessment of wheel running activity. Mice were individually
housed in polycarbonate cages equipped with running wheels. Mice were
kept under the LD cycle for a minimum of 10 d and then released into
constant darkness (DD) to establish stable free-running activity rhythms
for at least 14 circadian cycles. Each revolution of the running wheel
depressed an externally mounted microswitch, the activation of which
was recorded via a PC using the collect module of the ClockLab (Actime-
trics). Wheel revolution counts were analyzed and actograms were
double-plotted using ClockLab software (Actimetrics). Endogenous cir-
cadian periods (tau) were calculated by  2 periodogram in ClockLab.
Body weight and composition analysis. All mice were weighed during
the course of the experiments to monitor body weight with respect to
food intake (FI), wheel-running behavior, and general health. Cohorts of
male and female mice of the four genotypes were killed to quantify fat
deposition with respect to age. Subcutaneous fat and epididymal fat de-
pots were dissected and weighed.
Analysis of FI and metabolism. Locomotion, FI, water intake, and re-
spiratory exchange ratio (RER) were concurrently recorded using the
Comprehensive Laboratory Animal Monitoring System (CLAMS; Co-
lumbus Instruments) as previously described (Inutsuka et al., 2014).
Male mice (8 weeks old) were individually placed in CLAMS cages and
monitored for 5 d, the first 3 d of which were an acclimation period. Food
and water consumption was measured directly, and x/z ambulatory
activity (a minimum of 3 different, consecutive horizontal beam
breaks in counts) was used as the locomotion index. Data were col-
lected every 10 min.
Glucose tolerance test. At 9 weeks of age, male mice housed in the
CLAMS were fasted overnight for 16 h and then injected with 2 g/kg
dextrose (i.p.) at ZT2. Blood glucose levels were measured using the
ACCU-CHEK Nano meter (Roche Diagnostics). Blood samples were
obtained by carefully pricking the tail vein using a sterile needle. Area
under the curve was calculated with fasting glucose as the baseline.
Experimental design and statistics
In vitro electrophysiology. Patch-clamp recording data were analyzed us-
ing Clampfit 9 (Molecular Devices) and synaptic events using Mini-
Analysis (Synaptosoft). The nonparametric Kolmogorov–Smirnov test
(MiniAnalysis) was used to quantify the effects of photostimulation on
sEPSC and sIPSC frequency for each group. Sample traces were gener-
ated with Igor Pro version 6 (WaveMetrics) and graphs produced with
Prism 5 (GraphPad). For cell-attached recordings, spiking activity was
averaged in 30 s bins. A baseline period of 4 min before photoillumina-
tion was averaged and compared with the same period length 1 min into
light application, immediately upon light cessation, and 9 min after the
end of the light application. Vm was determined in 30 s bins for a mini-
mum period of 2 min before intervention. These data were then used to
calculate the average baseline Vm or RMP. The effects of interventions on
Vm were compared with this average baseline and the delta calculated.
For voltage-clamp analyses, cells were included if the peak current was
greater than the mean  2 SD of the preceding baseline value. To assess
characteristics of glutamatergic events between genotypes, 200 events per
baseline period were taken for analysis. Unless otherwise stated, data are
presented as mean  SEM, with n  number of cells per group (repre-
sented in parentheses for figures). We compared group means from the
same cells using paired t tests or one-way ANOVA followed by Newman–
Keuls post hoc tests; changes over time were analyzed by repeated-
measures ANOVA or two-way ANOVA followed by the Bonferroni or
Newman–Keuls post hoc test; different groups of cells were then com-
pared using unpaired t tests.
Tethered EEG/EMG recordings. SleepSign software was used to score 4 s
epochs of waking (W), NREM, and REM sleep according to standard
criteria (Yamanaka et al., 2002). All vigilance state classifications assigned
by SleepSign were confirmed following a visual examination by an inde-
pendent scorer, blinded to genotype and experimental condition. Spec-
tral analysis of the EEG was performed by fast Fourier transform
(sampled at 128 Hz), yielding a power spectra profile over a 0 – 40 Hz
window with a 1 Hz resolution divided into delta (1–5 Hz), theta (6 –10
Hz), alpha (10 –13 Hz), and beta (13–25 Hz) waves. An average EEG
spectrum profile was calculated from EEG power densities in each fre-
quency bin and then expressed as average power values in the delta, theta,
alpha, and beta bands for each state. Data were analyzed by unpaired t
test, paired t test, one-way ANOVA, or two-way ANOVA, as appropriate
for the parameters examined, using KaleidaGraph 4.0 (Hulinks). When
appropriate, ANOVA tests were followed by post hoc analysis of signifi-
cance using Fisher’s Protected Least Significant Difference test. p  0.05
was considered statistically significant.
Telemetry EEG/EMG recordings. EEG data from mice were scored in
10 s epochs by experts (96% interrater reliability) using NeuroScore 2.1
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(Data Sciences International). Epochs were classified as wakefulness
(mixed-frequency, low-amplitude EEG and high-amplitude, variable
EMG); wakefulness with wheel-running; REM sleep (theta-dominated
EEG and EMG atonia); NREM sleep (low-frequency, high-amplitude
EEG and low-amplitude, steady EMG); or cataplexy. Data were analyzed
as time spent in each state. To assess sleep intensity, EEG spectra during
NREM sleep were computed using the fast Fourier transform algo-
rithm in NeuroScore (Data Sciences) on all 10 s epochs without visu-
ally detectable artifact. EEG delta power (0.5– 4 Hz) in NREM sleep
(NRD) was calculated. NRD during the recovery after SD was nor-
malized to each animal’s average NRD during the 24 h baseline re-
cording. Wheel-running activity (OA) was classified if mice spent
	90% of an epoch running in the wheel. OA was included in percent
time calculations for wakefulness, but OA epochs were excluded from
the spectral analysis of wake due to high theta activity. NREM sleep
latency was determined as the time between light onset and the first 1,
3, or 6 consecutive epochs of NREM sleep; REM sleep latency was
determined as the time between light onset and the first 1, 2, or 3
consecutive epochs of REM sleep. When ANOVA indicated signifi-
cance, contrasts between relevant factor levels were detected with post
hoc Bonferroni t tests with   0.006 (see Table 4) and   0.02 (see
Fig. 5C) to correct for multiple comparisons.
Results
Specific expression of Arch in Hcrt/orexin neurons
Transgenic mice were generated in which Hcrt/orexin neurons
expressed Arch under control of the human prepro-orexin pro-
moter (orexin/Arch transgenic mice). This 3.2 kb DNA fragment
(Fig. 1A) has been used previously to express exogenous genes in
the Hcrt/orexin neurons (Sakurai et al., 1999, 2005; Hara et al.,
2001; Yamanaka et al., 2003a; Tsujino et al., 2005). Since Arch
was expressed as a fusion protein with GFP, Arch expression in
Hcrt/orexin neurons was confirmed by double-labeled immuno-
histochemistry using an anti-GFP antibody. Only 1 of 12 trans-
genic orexin/Arch mouse lines (line D3) expressed Arch in Hcrt/
orexin neurons; consequently, line D3 was used for all subse-
quent in vitro and in vivo experiments. A merged picture of
GFP-IR and orexin-IR revealed that Arch was exclusively ob-
served in 78.5  1.9% of the total orexin-IR population in line D3
(n  3; Fig. 1B). In this population, Arch was found in 81.9 
2.2% of orexin-A-IR cells (n  5; Fig. 1C, red channel) and 85.3 
2.9% of the orexin-B-IR-expressing cells (n  5; Fig. 1C, blue
channel). Arch expression (Fig. 1B,C, green channel) was not
found in any other cell type within the brain. GFP-IR was also
present in the dendrites as well as somata of Hcrt/orexin neurons.
Hcrt/orexin neurons expressing Arch did not show blebbing or
other features indicative of inappropriate trafficking.
We did not find any differences in the total number of orexin-IR
neurons between mice from the orexin/Arch D3 line and WT mice
(data not shown). Analysis of key downstream targets of the Hcrt/
orexin neurons (the locus coeruleus (LC), tuberomammillary nu-
cleus, and dorsal raphe nucleus) demonstrated Arch colocalization
in the terminal fields of orexin-expressing neurons (Fig. 1D).
Figure 1. Archaerhodopsin (Arch) expression in Hcrt/orexin neurons in the orexin/Arch transgenic mouse brain. A, Schematic of transgene used to express Arch downstream of the prepro-orexin
promoter. B, Top, Immunostaining of Hcrt/orexin-IR neurons (Alexa-594, red) located in the LHA. Middle, GFP-IR neurons (Alexa-488, green), reporting Arch expression, are also observed in the LHA.
Bottom, Merged picture showing expression of Arch within Hcrt/orexin neurons in the LHA of the orexin/Arch transgenic mice. Scale bars: left column, 300 m; right column, 50 m. Arch expression
was not observed in nonorexin neurons in any brain region. C, Arch expression was observed in the dendrites as well as somata of identified orexin-A-IR (red channel) and orexin-B-IR neurons (blue
channel). Scale bar, 50 m. Approximately 80% of Hcrt/orexin neurons colocalized with Arch. D, Immunohistochemistry demonstrates Arch expression in orexin-innervated regions, such as the
tuberomammillary nucleus (TMN), locus coeruelus (LC), and dorsal raphe nucleus (DRN). E, In vitro functionality and sensitivity of the Arch proton pump expressed in Hcrt/orexin cells of orexin/Arch
mice. Representative examples demonstrating that 575  25 nm illumination of Hcrt/orexin neurons from orexin/Arch mice results in a reduction in firing rate in both (Ei) cell-attached and (Eii)
current-clamp configurations. F, Yellow light stimulation (575  25 nm, orange bar) significantly reduced the firing activity of orexin/Arch neurons in cell-attached configuration. G, Photoactivation
of Arch similarly reduced electrical firing with concomitant hyperpolarization of the membrane potential in current-clamp recordings of Hcrt/orexin neurons. *p  0.05; ***p  0.001. Values are
mean  SEM
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In vitro functionality of Arch-expressing
Hcrt/orexin neurons
To confirm that photoactivation of Arch silenced Hcrt neurons,
whole-cell patch-clamp recordings from ex vivo brain slices were
performed. Both male and female juvenile (P14-P27) and adult
(	8 weeks of age) mice were studied. Application of whole-field
yellow light (575  25 nm) decreased firing activity in both cell-
attached and current-clamp recording configurations (Fig. 1E).
Quantification of cell-attached spiking activity from orexin/Arch
neurons indicated a basal firing rate of 2.95  0.05 Hz (n  20;
Fig. 1F), which was significantly reduced during photoillumina-
tion to 1.29  0.19 Hz (one-way ANOVA, F(3,19)  6.79, p 
0.0001). A rebound in spiking activity occurred after the termi-
nation of light (4.23  0.12 Hz, p  0.01) before resuming a
steady-state firing rate not dissimilar to baseline (3.58  0.4 Hz).
In current clamp (Fig. 1G), Hcrt/orexin neurons exhibited an
inhibitory response in both firing frequency and membrane po-
tential (Vm) in response to photoillumination. Prelight applica-
tion firing frequency averaged 2.46  0.6 Hz (n  17), which was
significantly reduced to 0.45  0.2 Hz (one-way ANOVA,
F(2,16)  4.59, p  0.0001). Post phototillumination firing fre-
quency was 1.32  0.34 Hz. Vm was 54.07  1.43 mV before
yellow light application and significantly hyperpolarized to
72.87  2.48 mV (n  33) at yellow light initiation, reaching a
steady state of 66.88  1.72 mV (one-way ANOVA, F(4,32) 
9.29, p  0.0001; Fig. 1F). Upon cessation of yellow light, Vm
returned to prestimulation levels (55.73  1.48 mV). These
data demonstrate efficient optical inhibition of Hcrt/orexin neu-
ronal excitability in orexin/Arch mice.
In vivo photoinhibition of Hcrt/orexin neurons induces
NREM sleep
Having demonstrated that Arch activation in vitro inhibits the
electrical activity of Hcrt/orexin neurons, we next examined the
effects of in vivo bilateral photoinhibition of these neurons on
sleep–wake states. First, the spontaneous sleep–wakefulness pat-
tern of orexin/Arch transgenic mice was analyzed to determine
whether the presence of the Arch transgene affected normal
sleep–wakefulness regulation. We compared the sleep–wakeful-
ness episode durations and total time in each state in freely
moving orexin/Arch transgenic mice to WT littermate mice.
Neither the episode duration nor total time in state differed
significantly between the two genotypes in either the light or
dark phases (Table 1). These results suggest that sleep–wake-
fulness patterns were unaffected by Arch expression in Hcrt/
orexin neurons.
To study the physiological significance of Hcrt/orexin neuro-
nal activity in the regulation of sleep–wakefulness, we performed
in vivo photic illumination of the LHA in freely moving orexin/
Arch transgenic mice. When green light (555  28 nm) from an
LED light source was delivered to the LHA of orexin/Arch mice
for 60 s during periods of spontaneous wakefulness in the second
half of the light phase (13:00 –19:00), EEG power gradually in-
creased and EMG power gradually decreased, indicative of the
onset of NREM sleep (Fig. 2A). During the second half of the 60 s
photoillumination period, all orexin/Arch transgenic mice
showed NREM sleep (n  13; Fig. 2Aiii); REM sleep was not
observed during this brief illumination period (Fig. 2Aiv).
Within a few seconds after termination of photic illumination,
the EEG showed fast waves and increased EMG levels occurred,
indicative of wakefulness (Fig. 2Ai). After a brief period of wake-
fulness (Fig. 2Aii), mice tended to fall asleep again without any
further activation of Arch via photoillumination (Fig. 2Aiii). In
contrast, when the same photoillumination paradigm was ap-
plied to bilaterally implanted WT littermates, no observable
changes in sleep–wake parameters were recorded (data not
shown). Furthermore, green light illumination of the LHA of
freely moving orexin/Arch transgenic mice (n  9) had no effect
on sleep or wakefulness during the dark phase (21:00 –23:00;
ZT13-ZT15) when nocturnal mice have high levels of spontane-
ous activity and arousal.
Since mice can normally be awakened by tactile stimulation
during spontaneous sleep, we evaluated whether orexin/Arch
mice were similarly sensitive during photoillumination-induced
NREM sleep. Approximately 50 s after initiating photoillumina-
tion in the light phase between ZT7-ZT9, orexin/Arch transgenic
mice were stroked with an artist’s brush during green light-
induced NREM sleep. As soon as orexin/Arch mice were stimu-
lated, desynchronized activity occurred in the EEG and increased
EMG levels were observed, indicative of an awakening from sleep.
All orexin/Arch transgenic mice (n  9) showed transitions from
NREM to wakefulness after tactile stimulation. These results in-
dicate that the cessation of activity induced by photic illumina-
tion is different from paralysis and similar to physiological
NREM sleep.
Efficacy of in vivo green light illumination to change sleep–
wake states in orexin/Arch mice is dependent upon time of day
Having determined that acute (1 min) photoinhibition of Hcrt/
orexin neurons in orexin/Arch mice can induce NREM sleep, we
evaluated whether prolonged (1 h) illumination would also be
effective and whether any effects observed varied across the 24 h
period. In contrast to brief 1 min photoillumination, green illu-
mination of the LHA for 1 h periods delivered during the light
phase from ZT0-ZT1, ZT5-ZT6, or ZT8-ZT9 (Fig. 2Bi) did not
significantly affect arousal states relative to control (Fig. 2Bii). In
contrast, when green illumination was delivered to the LHA just
after dark onset (ZT12-ZT13) or 4 h later from ZT16-ZT17 (Fig.
2Ci), the time spent awake decreased (Fig. 2Cii; basal 39.4  2.4
min vs stim 25.6  2.7 min, n  10; p  0.0004, paired t test) and
the time in NREM increased (basal 19.7  2.2 min, stim 32.8 
2.4 min, n  10; p  0.0001, paired t test). The EEG spectra
during photoillumination of orexin/Arch mice was indistinguish-
able from sleep–wake of WT mice (Fig. 2-1, available at https://
doi.org/10.1523/JNEUROSCI.0311-19.2019.f2-1). Locomotor
activity (LMA) also decreased during light stimulation and the
number of the transitions between states increased (Fig. 2Cii).
Table 1. Average episode duration and total time of each vigilance state recorded
from transgenic orexin/Arch and littermate WT micea
Parameter State WT mice (n  5) Orexin/Arch mice (n  5)
Light phase
Episode duration (s) Wake 146.6  10.4 128.5  15.3
NREM 279.2  27.1 296.0  33.3
REM 96.7  7.6 83.2  4.6
Total time (min) Wake 231.4  18.7 200.2  8.5
NREM 434.1  16.9 464.9  8.9
REM 54.5  2.3 54.9  6.3
Dark phase
Episode duration (s) Wake 426.9  81.6 322.2  75.8
NREM 362.9  87.8 259.3  36.3
REM 84.4  4.2 77.2  4.5
Total time (min) Wake 399.1  36.2 372.1  25.7
NREM 288.2  31.5 316.8  20.9
REM 32.8  5.9 31.1  5.2
aValues are mean  SEM. Wake, Wakefulness; NREM, non-Rapid Eye Movement Sleep; REM, Rapid Eye Movement
Sleep.
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Green light stimulation delivered toward the end of the dark
phase from ZT20-ZT21 was ineffective, as during the light phase.
Inhibition of Hcrt/orexin neuronal activity by green light
illumination in vivo
To determine whether green light activation of Arch affected
Hcrt/orexin neurons in vivo, we examined c-FOS expression in
Hcrt/orexin neurons. We compared orexin/Arch transgenic mice
exposed with 1 h green light stimulation beginning at ZT12 (n 
6) and sham (nonilluminated) controls (n  6) (Fig. 2Di). The
proportion of orexin-IR neurons expressing c-FOS-IR was sig-
nificantly reduced in orexin/Arch mice subjected to green light
illumination (Fig. 2Dii; controls 69.6  6.1%, illuminated 2.6 
1.1%; p  0.0001, unpaired t test), demonstrating a robust reduc-
tion in Hcrt neural activity during illumination.
Arch expression levels change the sensitivity
to photoillumination
qPCR reflecting transgene copy number distinguished two sub-
groups of orexin/Arch mice: low (aLE) or high (aHE) Arch ex-
pressers (Fig. 3A). Analysis was performed to determine whether
age (juvenile: P14 –P27; adult: 	8 weeks) and transgene expres-
sion level contributed to the efficacy of photoinhibition on Hcrt/
orexin neuron activity and behavior. We hypothesized that
higher Arch expression levels, reflected by higher qPCR values,
would be more effective in silencing Hcrt/orexin neurons when
photoilluminated. Cell-attached electrophysiological recordings
did not distinguish significant differences in prestimulation spik-
ing activity among the groups (adult aLE: 2.14  0.07 Hz, n  3;
juvenile aLE: 3.07  0.58 Hz, n  7; adult aHE: 3.71  0.70 Hz,
n  5; juvenile aHE: 2.34  0.67 Hz, n  6; one-way ANOVA,
F(3,17)  1.05, p  0.39). Upon 5 min photoillumination, how-
ever, Hcrt/orexin neuron firing frequency was significantly re-
duced in all groups, except juvenile aLE mice in which Hcrt/
orexin neuronal firing began to disinhibit within 
3– 4 min
despite continued light stimulation (Fig. 3B). Upon cessation of
photoillumination, spiking activity rebounded in all groups
(adult aLE: 3.22  0.05 Hz, n  3; juvenile aLE: 4.33  0.09 Hz,
n  7; adult aHE: 5.16  0.22 Hz, n  5; juvenile aHE: 3.75 
0.11-hz, n  6; one-way ANOVA, F(15,7)  62.08, p  0.0001)
before returning to prestimulation levels.
In current clamp, photoillumination significantly hyperpo-
larized the Vm of Hcrt/orexin neurons in all orexin/Arch mice
tested (Fig. 3C; adult aLE:   39.48  2.52 mV, n  5; juvenile
aLE:   18.85  4.38 mV, n  10; adult aHE:   13.76 
1.18 mV, n  11; juvenile aHE:   16.08  2.08 mV, n  7;
two-way ANOVA, p  0.001). In addition, yellow light illumina-
tion reduced the firing frequency in aLE mice (Fig. 3D; adult:
baseline 3.37  0.4 Hz vs light pulse 0.25  0.2 Hz, two-way
repeated-measures ANOVA, p  0.001; juvenile: baseline 3.88 
1.33 Hz vs light pulse 1.19  0.5 Hz; two-way repeated-measures
ANOVA, p  0.001). Unexpectedly, aHE mice had lower baseline
Figure 2. Bilateral in vivo green light stimulation activates Arch and silences Hcrt/orexin neurons. Ai, Acute 1 min photoillumination applied at random intervals during wake bouts between ZT8
and ZT11 decreased the probability of wake (Aii) and increased NREM sleep (Aiii) but not REM sleep (Aiv). Bi, Longer 1 h photoillumination between ZT8 and ZT9 did not change the total time spent
in sleep versus wake (Bii) compared with baseline conditions. Ci, In contrast, when 1 h green light was applied between ZT16 and ZT17, a significant increase in NREM sleep and concomitant
reductions in both wake and LMA (Cii) occurred during photoillumination. The EEG spectra during photoillumination at any time of day were indistinguishable from sleep–wake of WT mice (Fig. 2-1,
available at https://doi.org/10.1523/JNEUROSCI.0311-19.2019.f2-1). Di, One hour photoillumination beginning at ZT12 resulted in a decrease of c-FOS in orexin-IR neurons. Top, Black triangles
represent double-labeled c-FOS  Hcrt/orexin neurons. Bottom, Open triangles represent c-FOS  Hcrt/orexin neurons. Open triangles represent orexin  neurons. Dii, Bar graph represents the
percentage of Fos  orexin neurons (n  11 for control, n  12 for light illumination). Values are mean  SEM. *p  0.05 versus prelight application.
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Figure 3. Differential Arch expression levels in orexin/Arch mice cause aberrant electrophysiological properties of Hcrt/orexin neurons and result in a gradient of photoinhibition.
A, qPCR results distinguished two subgroups of orexin/Arch mice, low- (aLE) or high- (aHE) Arch expressers, based on gene copy number. B, Cell-attached recordings in response to 5 min
photoillumination (orange line, 575  25 nm) grouped by age (juvenile: P14 –P27; adult: 	8 weeks) and Arch expression. In contrast to juvenile aLE mice, adult orexin/Arch mice
exhibited photoinhibition throughout the illumination period. Upon cessation of photoillumination, there was a significant rebound in spiking activity, before the firing rate returned
toward prestimulation levels. C, Summary data indicate that photoillumination silenced Hcrt/orexin neuronal activity. However, Hcrt/orexin neurons in aHE mice of both ages (purple)
had hyperpolarized RMPs (Vm) and (D) a lower basal firing rate. E, Photoillumination evoked a significant outward current (Io) with different light durations (Ei). Photoillumination also
decreased sEPSCs onto Hcrt/orexin neurons in aLE mice (Eii). Further characterization of basal sEPSC activity (Eiii) indicated no difference in sEPSC amplitude between Hcrt/orexin
neurons from orexin/Arch and orexin/eGFP mice, although there was a significant reduction in the frequency of glutamatergic events that was more pronounced in aHE mice. F, When
photoillumination was applied in conditions to measure sIPSCs, yellow light (575  25 nm) evoked an outward current in all groups (Fi), but sIPSC activity did not change (Fii).
Nevertheless, basal GABAergic tone was altered in orexin/Arch mice relative to orexin/eGFP mice, with a larger amplitude of basal events and greater sIPSC frequency (Fiii). G, Bath
application of oxytocin (300 nM), a known activator of Hcrt/orexin neurons, had differential effects on the excitability of Hcrt/orexin neurons in (Gi) aLE and (Gii) aHE orexin/Arch mice:
oxytocin significantly depolarized Vm of Hcrt/orexin neurons from aLE mice but not aHE mice (Giii). Values are mean  SEM. *p  0.05, **p  0.01, ***p  0.001; n.s., non-significant
as in legends to Figures 4 and 5.
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firing rates than aLE mice (adult: 1.16  0.7 Hz, n  4; juvenile:
0.40  0.2 Hz, n  4; one-way ANOVA, p  0.03) and yellow
light completely inhibited firing, yet statistical significance was
not reached (two-way ANOVA, p 	 0.05). Overall, the RMP of
aLE mice was comparable with Hcrt/orexin neurons of orexin/
eGFP mice (aLE: 46.59  1.20 mV, n  15; eGFP: 51.30 
2.68 mV, n  5; one-way ANOVA, p 	 0.05), but neurons from
aHE mice were significantly hyperpolarized (aHE: 59.89  1.38
mV, n  22; p  0.01), even in the absence of yellow light illumi-
nation. Nonorexin neurons, which did not have GFP fluores-
cence, showed no response to yellow light illumination in either
orexin/EGFP or orexin/Arch mice (data not shown).
Yellow light illumination induces an outward current in
Arch-expressing Hcrt/orexin neurons
Since yellow light illumination reduced the Vm and inhibited
firing of Arch-expressing Hcrt/orexin neurons, we assessed the
magnitude of light-evoked current. In voltage clamp, yellow light
stimulation of different durations (1, 2, and 5 min) evoked an
outward current in all groups tested, although age and transgene
expression levels affected the magnitude of the current (Fig. 3Ei).
Juvenile aLE mice had the smallest average current evoked
(10.99  1.60 pA, n  21). In contrast, photo-induced currents in
juvenile aHE mice (26.44  1.84 pA, n  68) were significantly
greater (one-way ANOVA F(3,156)  5.07, p  0.02) and compa-
rable with those of Hcrt/orexin neurons from adult aLE mice
(24.33  2.68 pA, n  19) yet significantly lower than for adult
aHE recordings (52.86  2.90 pA, n  52; Fig. 3Ei). These results
suggest that the magnitude of the photoinduced currents evoked
is related to the degree of Arch expression in Hcrt/orexin
neurons.
Yellow light illumination differentially affects glutamatergic
inputs to Hcrt/orexin neurons in aLE versus aHE mice
Since Hcrt neurons are thought to release glutamate and mutu-
ally innervate each other, we next determined the effect of yellow
light stimulation on glutamatergic tone (Fig. 3Eii). The frequency
of sEPSCs was significantly reduced following yellow light stim-
ulation in aLE Hcrt/orexin neurons (juvenile:   35.21 
0.82%, n  3; adult:   55.72  4.8%, n  3; one-way
ANOVA, p  0.01 and p  0.001, respectively). In contrast, this
response was not seen in either aHE age group.
Photoinhibition of Hcrt/orexin neurons does not affect
GABAergic tone
We also analyzed the effect of photoillumination on Arch-
expressing neurons in relation to sIPSCs (Fig. 3F). Under these
conditions, yellow light inhibition evoked significant outward
currents in all groups (juvenile aLE:  12.20  2.41 pA, n  5;
adult aLE:  15.52  2.63 pA, n  5; juvenile aHE:  29.45  2.73
pA, n  8; adult aHE:  49.92  8.44 pA, n  6; one-way
ANOVA, F(3,20)  11.68, p  0.0001; Fig. 3Fi), but the change in
sIPSC frequency did not differ across groups (Fig. 3Fii). Thus,
unlike sEPSC activity, photoillumination of Arch in Hcrt/orexin
neurons did not affect sIPSC activity.
Increased expression of Arch affects basal properties of Hcrt/
orexin neurons
As discussed above, the Hcrt/orexin neurons of aHE mice had
significantly hyperpolarized RMP and decreased basal firing rates
yet exhibited the largest change in Vm and outward current dur-
ing photoillumination and activation of Arch. Therefore, we de-
termined whether Arch transgene expression modified Hcrt/
orexin neuronal function without direct activation of Arch by
photoillumination. Further analysis of sEPSC basal tone (Fig.
3Eiii) indicated that sEPSC event amplitude was similar in orexin/
eGFP (21.83  1.07 pA, n  5) and orexin/Arch mice (aLE:
19.76  1.89 pA, n  6; aHE: 20.23  1.28 pA, n  10; one-way
ANOVA, F(2,18)  1.63, p  0.44). However, Arch expression
significantly reduced sEPSC frequency, particularly in Hcrt/
orexin neurons from the aHE cohort (eGFP: 22.02  4.02 Hz,
n  5; aLE: 10.14  1.93 Hz, n  6; aHE: 6.21  1.13, n  10;
one-way ANOVA, F(2,18)  13.72, p  0.0002). These observa-
tions may explain why photoinhibition of sEPSC activity was
only found in Hcrt neurons from aLE mice (i.e., there was a floor
effect in cells from aHE mice).
In addition, sIPSC amplitude (Fig. 3Fiii) was significantly in-
creased in orexin/Arch mice (eGFP: 10.23  1.32 pA, n  6; aLE:
24.81  3.55 pA, n  11; aHE: 30.05  3.55 pA, n  12; one-way
ANOVA, F(2,26)  7.61, p  0.02). A significant increase in sIPSC
frequency also occurred (eGFP: 2.60  0.43 Hz, n  11; aLE:
5.56  0.66 Hz, n  10; aHE: 5.83  0.67 Hz, n  13; one-way
ANOVA, F(2,31)  8.63, p  0.001), suggesting a change in the
excitatory properties of Hcrt/orexin neurons. Together, these
changes in basal excitatory-inhibitory drive in the absence of
photoillumination indicate that the presence of the Arch
transgene reduced Hcrt neuron excitability in an expression-
dependent manner.
To determine whether these changes affected the response of
Hcrt/orexin neurons to a known activator of these cells, we ap-
plied oxytocin (300 nM) to Hcrt/orexin neurons from orexin/Arch
mice. In aLE mice (Fig. 3Gi), oxytocin significantly depolarized
Hcrt/orexin neurons (  4.52  1.11 mV, n  7; repeated-
measures ANOVA, F(2,6)  18.60, p  0.0006), evoking firing
activity in some cells. This response was absent in aHE mice ( 
0.24  0.53 mV, n  8; repeated-measures ANOVA, F(2,7) 
0.23, p  0.78; Fig. 3Gii). Oxytocin (300 nM) significantly in-
creased Vm in Hcrt/orexin neurons from aLE mice but not
from aHE mice (Fig. 3Giii). These data indicate that high
expression levels of the Arch transgene modify the electrical
properties of Hcrt neurons independently from its opsin func-
tion, which may affect other behaviors that are dependent on
Hcrt/orexin signaling.
Orexin/Arch mice exhibit aberrant metabolic characteristics
Hcrt/orexin neurons are known to exert effects on motor activity
and metabolic parameters. As shown in Figure 3, multiple
changes in electrophysiological characteristics of Hcrt/orexin
neurons occur in 8-week-old orexin/Arch mice with high expres-
sion of the Arch transgene (aHE orexin/Arch mice). Conse-
quently, we assessed whether these changes observed in vitro were
reflected in changes in metabolism in vivo. Using the CLAMS, we
measured 48 h FI, x and z activity, and RER in aLE and aHE
orexin/Arch mice, ATAX mice, and WT mice during the light,
dark, and 24 h periods (Fig. 4A). ATAX mice are an established
model of Hcrt/orexin cell loss that mimic an NT1-like phenotype
(Hara et al., 2001).
ATAX mice (n  4) consumed significantly less food (Fig.
4Aii, top) than the other genotypes across the time periods ana-
lyzed (light: 0.07  0.008 g/h; dark: 0.12  0.004 g/h; 24 h: 0.09 
0.006 g/h; two-way ANOVA: F(3,15)  7.59, p  0.003 for time;
F(2,30)  228.25, p  0.0001 for genotype). During the light phase,
aHE mice ate amounts comparable with ATAX mice (light:
0.08  0.008 g/h vs WT light: 0.11  0.003 g/h) but less than
either aLE or WT mice.
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x and z activity counts did not differ among genotypes across
the 24 h period (Fig. 4Aii). However, both orexin/Arch subgroups
exhibited increased activity during the dark phase relative to WT
mice (x activity: WT: 1963.35  118.6 beam breaks, aLE:
2792.10  421.2 beam breaks, aHE: 2681.65  280.68 beam
breaks; p  0.01 for genotype by two-way ANOVA).
Surprisingly, significant differences in RER occurred between
WT mice and both subgroups of orexin/Arch mice (Fig. 4Aii,
bottom). During the light phase, aHE mice had significantly
lower RER than WT (aHE: 0.81  0.01; WT: 0.88  0.003), but
aLE mice had increased RER (aLE: 0.92  0.012; p  0.0004 for
genotype by two-way ANOVA). During the dark phase, both
Figure 4. Aberrant circadian and metabolic features of orexin/Arch mice compared with orexin/Ataxin-3 (ATAX ) and WT mice. A, Hourly metabolic rate over a 48 h period (Ai) and summed for the
light, dark, and 24 h periods (Aii) revealed reduced FI, z activity, and RER during the dark phase in ATAX mice and reduced FI and RER in aHE mice during the light phase relative to other strains. Both
aLE and aHE mice had greater x activity and RER during the dark phase relative to other strains. B, By 12 weeks of age, the body weight of orexin/Arch aHE mice exceeded that of both WT and ATAX
mice. Inset, Body weight trajectory with age across the different strains using a line of best fit for each genotype (0.83 	 R 2 	 0.90). C, Age-matched mice were used to assess postmortem body
composition; aHE orexin/Arch mice had significantly elevated adiposity, particularly increased epididymal and subcutaneous fat mass. D, Male mice (9 weeks) were fasted overnight for a glucose
tolerance test; no significant differences were observed across genotypes. E, Representative wheel-running actograms represent comparable locomotor rhythms between WT and aLE orexin/Arch
mice under both LD (yellow bar: gray bar) and DD (gray shaded area) conditions. In contrast, aHE orexin/Arch mice have greatly reduced running wheel activity. Two-way ANOVA with Bonferroni post
hoc test: *p  0.05; **p  0.01; ***p  0.001. Abd, Abdominal fat; EpD, epididymal fat pad; SubQ, subcutaneous fat pad.
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subgroups of orexin/Arch mice had significantly higher RER val-
ues than WT mice. Together, these data indicate metabolic
abnormalities in orexin/Arch mice, presumably due to an unex-
pected transgene effect on Hcrt/orexin neuronal function.
Phenotypic abnormalities in aHE orexin/Arch mice
As described above, data collected in the CLAMS instrument
indicated aberrant physiology in orexin/Arch mice that was dis-
tinct from that of ATAX mice. To more thoroughly investigate
energy metabolism, we assessed growth rate, body composition,
glucose tolerance, and circadian control of locomotor activity.
Body weight varied significantly across genotypes with age
(Fig. 4B). At 3– 4 months, the body weight of aHE mice (35.71 
1.13 g, n  7) exceeded that of all other groups (WT: 30.37 
1.11 g, n  10; aLE: 31.70  1.33 g, n  10; ATAX: 30.17  0.89 g,
n  6; one-way ANOVA, F(3,29)  3.93, p  0.02). By 14 –16
months (Fig. 4B, inset), both aHE and ATAX mice were obese
relative to either WT or aLE mice but were not significantly dif-
ferent from each other (WT: 39.80  2.15 g, n  5; aLE: 42.33 
0.98 g, n  6; aHE: 56.80  1.79 g, n  10; ATAX: 55.20  4.03 g,
n  5; one-way ANOVA, F(3,22)  14.68, p  0.0001).
Since body weight was altered in aHE mice and ATAX mice,
we assessed whether this was due to increased fat mass. Mice from
all groups were killed at various ages (Fig. 4C, inset) and the fat
pads weighed (Fig. 4C). We found that epididymal and subcuta-
neous fat mass was comparable between ATAX (n  6) and aHE
mice (n  14). The increase in both aHE fat pads was significantly
different from WT (n  10; two-way ANOVA, p  0.05 for
epididymal and subcutaneous).
We also assessed glucose tolerance in mice before age-related
fat mass changes to determine whether fasting glucose levels pre-
dicted increased body weight in later life. A glucose tolerance test
performed after overnight fasting did not reveal any significant
differences in glucose tolerance among the strains examined (Fig.
4D; one-way ANOVA, F(2,9)  1.96, p  0.19).
Since the circadian clock has been linked to metabolic regula-
tion, we measured wheel-running activity under LD and DD con-
ditions as an index of clock function in adult mice. Mice were
acclimated to running wheels for 5 d before assessing voluntary
measures of circadian locomotor activity (Fig. 4E; Table 2). Al-
though mice of all strains entrained to an LD cycle, there were
clear differences in the amount of running wheel activity across
strains (two-way ANOVA, F(3,29)  3.03, p  0.004) with aHE
mice being the least active. The reduced activity in both aHE and
ATAX mice was significant under DD (two-way ANOVA, p 
0.045; Bonferroni post hoc test, p  0.01 for aHE vs WT and p 
0.05 for ATAX vs WT). In DD conditions, the endogenous period
of ATAX mice remained close to 24 h and was thus significantly
longer than all other genotypes (p  0.001). There was no signif-
icant genotype  time interaction for circadian amplitude (two-
way ANOVA, F(3,29)  2.18; p  0.11).
FI and body weight were also measured in mice that had access
to running wheels. FI was normalized to the body weight of each
individual mouse (Table 3). Although no significant differences
were found, there was a trend toward increased body weight gain
in aHE mice during DD compared with WT.
There was some variation in age (WT: 6.3  0.7 months, n 
7; aLE: 7.3  1.2 months, n  11; aHE: 9.1  2.2 months, n  6;
ATAX: 4.8  0.3 months, n  8) and body weight (WT  37.2 
2.6 g, aLE: 35.7  1.6 g, aHE: 47.6  5.8 g, ATAX: 33.1  1.2 g)
across strains of mice given access to running wheels. Since these
differences in age may have contributed to the differences in
wheel-running activity recorded, we removed the oldest aHE
mice from the analysis, which reduced the mean age of aHE mice
to 5.5  2.5 months (n  4). Nevertheless, the reduced wheel-
running of aHE mice in DD compared with WT persisted (aHE:
3.15  1.15 revolutions/min vs WT: 11.90  2.42 revolutions/
min; one-way ANOVA, p  0.04; data not shown).
ATAX and Orexin/Arch transgenic mice exhibit distinct
differences in sleep–wake architecture and EEG spectra
The sleep–wake patterns and EEG spectral features of aLE and
aHE orexin/Arch mice were compared with WT and with ATAX
mice, an established model of Hcrt/orexin cell loss that results in
NT1. Baseline recordings of sleep–wake suggested little difference
among strains in the hourly amounts of wakefulness (Fig. 5Ai,
left), but two-way repeated-measures ANOVA revealed a nomi-
nally significant genotype  time interaction when the data were
analyzed across the light and dark phases and the entire 24 h
period (F(6,48)  2.9; p  0.017; Bonferroni-corrected threshold
  0.006; Table 4). Wake bout architecture (Fig. 5Ai, right)
differed among strains with significant genotype  time interac-
Table 2. Diurnal and circadian parameters of running wheel activity rhythms in WT, orexin/Ataxin-3, and orexin/Arch transgenic mice
Mean revolutions/min Tau (h) Amplitude
Strain N LD DD LD DD LD DD
WT 8 8.56  2.59 11.11  2.22 24.02  0.03 23.77  0.05 2028  512 992  188
Orexin/Ataxin-3 8 4.42  1.28 4.39  1.39* 23.98  0.02 23.90  0.06***,### 1062  99 781  79
Orexin/Arch: aLE 11 9.74  1.39 9.35  1.71 23.98  0.02 23.70  0.06 4728  1183 ∧,† † 3495  904 †
Orexin/Arch: aHE 6 2.06  0.95 # 2.37  0.90**,# 24.00  0.03 23.61  0.13 ††† 1707  402 1486  434
2-way ANOVA F(3,29)  3.03; p  0.0452 F(3,29)  3.42; p  0.03 F(3,29)  2.18; p  0.112
*p  0.05; **p  0.01; ***p  0.001 versus WT.
†p  0.05; ††p  versus ATAX; †††p  0.001 versus ATAX.
#p  0.05; ###p  0.001 versus aLE.
∧p  0.05 versus aHE.
Table 3. Daily food consumption and weekly increase in body weight in Orexin/Arch, Orexin/Ataxin-3, and WT mice
Normalized FI (g/d) Body weight change (g/week)
Strain N LD DD LD (no wheels) LD DD LD (no wheels)
WT 5 0.31  0.01 0.33  0.02 0.31  0.02 0.40  0.25 0.53  0.17 0.73  0.19
Orexin/Arch: aLE 6 0.33  0.02 0.33  0.02 0.32  0.03 0.22  0.18 0.83  0.24 0.61  0.16
Orexin/Arch: aHE 3 0.30  0.02 0.28  0.02 0.27  0.02 0.55  0.40 1.44  0.29 0.44  0.40
Two-way ANOVA F(6,33)  0.64, p  0.694 F(6,33)  1.77, p  0.1363
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Figure 5. EEG phenotyping of male orexin/Ataxin-3 (ATAX ) and orexin/Arch mice reveals distinct differences in sleep–wake architecture and EEG spectral composition. A, Diurnal distribution of
wakefulness (Ai) and NREM sleep (Aii) in both aLE and aHE orexin/Arch mice is comparable with age-matched male WT mice but distinct from that of ATAX mice. However, the number of REM bouts
in aHE orexin/Arch mice was significantly increased over the 24 h period relative to the other strains (Aiii). Spontaneous cataplexy was only observed in ATAX mice (Aiv). Repeated-measures ANOVA
revealed strain differences in hourly LMA (Fig. 5-1 Ai, available at https://doi.org/10.1523/JNEUROSCI.0311-19.2019.f5-1) without a significant effect on Tb (Fig. 5-1 Aii, available at https://doi.org/
10.1523/JNEUROSCI.0311-19.2019.f5-1). B, The chocolate-cataplexy assay was used to determine whether cataplexy could be elicited in orexin/Arch mice under rewarding conditions. Presentation
of chocolate at ZT12 significantly increased time spent awake (Bi) and reduced NREM sleep (Bii) during the dark phase for all strains. The percent time in REM sleep (Figure legend continues.)
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tions for both the number of wake bouts (F(6,48)  14.4; p 
0.0001) and wake bout duration (F(6,48)  5.42; p  0.0002). Post
hoc analyses revealed that ATAX mice were the source of this
variation, exhibiting more wake bouts (p  0.001) of shorter
duration (p  0.001) during the dark phase compared with WT
mice.
Like wakefulness, the hourly percentage of NREM sleep did
not differ across strains (Fig. 5Aii) but, when examined across the
light and dark phases and the entire 24 h period, two-way
repeated-measures ANOVA revealed significant genotype 
time interactions (Table 4) for the number of NREM bouts
(F(6,48)  5.36; p  0.0003) and nominally significant NREM
bout duration (F(6,48)  3.02; p  0.014; Bonferroni-corrected
threshold   0.006). As during wakefulness, these differences
were due to the ATAX mice, which had more than twice as many
NREM bouts during the dark period compared with WT mice
(p  0.001; Fig. 5Aii, right).
In contrast to wake and NREM sleep, two-way repeated-
measures ANOVA revealed a significant genotype  time inter-
action in the hourly amount of REM sleep (F(69,552)  2.02; p 
0.0001; Fig. 5Aiii). Further analysis indicated that ATAX mice
had less REM sleep than WT during the 12 h light phase (p 
0.05), whereas aHE mice had more REM during this phase (p 
0.01) and more REM bouts across the entire 24 h period than WT
mice (p  0.01; Table 4).
Analysis of hourly LMA revealed a genotype  time interac-
tion (two-way repeated-measures ANOVA, F(69,552)  1.33; p 
0.04; Fig. 5-1Ai, left, available at https://doi.org/10.1523/
JNEUROSCI.0311-19.2019.f5-1) that may reflect, in part, the
tendency for older ATAX and aHE mice to exhibit reduced
wheel-running activity compared with WTs (Fig. 4E). When the
LMA data were binned into respective LD phases, however, the
genotype  time of day interaction was not significant (two-way
repeated-measures ANOVA, F(6,48)  1.80; p  0.12; Fig. 5-1Ai,
right, available at https://doi.org/10.1523/JNEUROSCI.0311-
19.2019.f5-1). Basal Tb was similar across strains when viewed
either hourly (two-way repeated-measures ANOVA, F(69,552) 
1.13; p  0.24) or when binned into the light and dark phases
(two-way repeated-measures ANOVA, F(6,48)  0.36; p  0.90;
Fig. 5-1Aii, available at https://doi.org/10.1523/JNEUROSCI.
0311-19.2019.f5-1).
Spontaneous cataplexy occurred exclusively in ATAX mice
and was only observed during the dark phase (Fig. 5Aiv). Since
Hcrt/orexin neurons appear to be hypofunctional in aHE orexin/
Arch mice, we used the CCA (Oishi et al., 2013) to determine
whether we could elicit cataplectic attacks in aHE mice. Under
the rewarding condition of the CCA, cataplexy increased sub-
stantially in ATAX mice (Fig. 5Biv vs Fig. 5Aiv) and was even
observed during the light phase but remained restricted to this
strain. Access to chocolate at the beginning of the dark phase
prolonged wakefulness (Fig. 5Bi vs Fig. 5Ai) and decreased
NREM sleep during the dark phase (Fig. 5Bii vs Fig. 5Aii) in all
genotypes. Chocolate availability at the beginning of the dark
phase also tended to displace REM sleep into the light phase
(Fig. 5Biii vs Fig. 5Aiii). LMA did not differ among genotypes
in the CCA (Fig. 5-1Bi, available at https://doi.org/10.1523/
JNEUROSCI.0311-19.2019.f5-1) nor did Tb (Fig. 5–1Bii, avail-
able at https://doi.org/10.1523/JNEUROSCI.0311-19.2019.f5-1).
LMA increased significantly during the CCA relative to base-
line only in aLE mice (two-way repeated-measures ANOVA,
4
(Figure legend continued.) also decreased, except in ATAX mice (Biii). Chocolate also robustly
increased cataplexy in ATAX mice but did not elicit cataplexy in orexin/Arch mice (Biv). Neither
LMA ( p  0.12; Fig. 5-1Bi, available at https://doi.org/10.1523/JNEUROSCI.0311-
19.2019.f5-1) nor Tb ( p  0.21; Fig. 5-1Bii, available at https://doi.org/10.1523/
JNEUROSCI.0311-19.2019.f5-1) was significantly different among genotypes in the CCA. C,
Spectral analysis of normalized EEG power across the active phase (ZT12-ZT23) and inactive
phase (ZT24-ZT11) indicated significant changes in different bands across sleep–wake states in
orexin/Arch mice during baseline recordings. During the 4 h SD, neither LMA ( p  0.87; Fig.
5-1Ci, available at https://doi.org/10.1523/JNEUROSCI.0311-19.2019.f5-1) nor Tb ( p  0.089;
Fig. 5-1Cii, available at https://doi.org/10.1523/JNEUROSCI.0311-19.2019.f5-1) differed across
strains. Bout D., Bout duration. Two-way ANOVA with Bonferroni post hoc test: *p  0.05;
**p  0.01; ***p  0.001 relative to WT.
Table 4. Basal sleep/wake parameters of WT, orexin/Ataxin-3, and orexin/Arch transgenic mice
Percentage of time No. of bouts Mean bout duration (min)
Strain N Light phase Dark phase 24 h Light phase Dark phase 24 h Light phase Dark phase 24 h
Wake
WT 8 29.91  0.96 71.08  3.35 50.49  1.81 81.12  6.22 40.25  4.38 109.75  9.04 2.59  0.19 14.24  2.45 6.96  0.78
Orexin/Ataxin-3 5 31.91  0.93 59.08  4.91 45.14  2.08 102.40  4.54* 97.00  6.46*** 192.00  9.04*** 2.09  0.11 4.45  0.68*** 3.34  0.34
Orexin/Arch: aLE 10 27.14  1.16 69.49  2.62 48.31  1.34 66.50  4.06 ††† 38.10  2.77 ††† 94.50  6.33 ††† 2.76  0.17 13.83  1.46 ††† 7.43  0.59 †
Orexin/Arch: aHE 5 27.85  1.69 65.51  1.88 46.68  1.68 62.40  9.06 †† 44.20  2.63 ††† 98.00  11.06 ††† 3.11  0.24 10.59  0.41 †† 6.86  0.50
Two-way RM ANOVA F(6,48)  2.9; p  0.017 F(6,48)  14.4; p  0.0001 F(6,48)  5.42; p  0.0002
NREM sleep
WT 8 58.79  1.25 26.64  3.03 42.72  1.94 153.75  7.46 62.25  7.28 209.00  11.12 2.77  0.10 3.14  0.21 2.95  0.10
Orexin/Ataxin-3 5 59.06  1.11 36.24  4.70 47.65  2.44 174.20  7.88 135.60  16.53*** 298.60  13.24*** 2.44  0.05 1.92  0.19 2.29  0.11
Orexin/Arch: aLE 10 61.31  1.71 27.81  2.20 44.56  1.37 162.00  7.88 71.50  7.00 ††† 225.10  12.99 ††† 2.77  0.15 2.86  0.16 2.90  0.15
Orexin/Arch: aHE 5 59.08  2.77 31.16  1.83 45.11  2.23 146.00  9.79 80.60  6.17 † 217.40  13.51 ††† 2.97  0.30 2.84  0.32 3.05  0.33
Two-way RM ANOVA F(6,48)  2.21; p  0.06 F(6,48)  5.36; p  0.0003 F(6,48)  3.02; p  0.014
REM sleep
WT 8 8.49  0.64 2.27  0.32 5.38  0.40 45.00  2.96 13.25  1.77 57.37  4.23 1.32  0.05 1.22  0.06 1.33  0.04
Orexin/Ataxin-3 5 6.30  0.45* 4.24  0.62 5.27  0.51 37.20  4.40 22.40  4.40 59.20  8.54 1.24  0.07 1.42  0.11 1.31  0.06
Orexin/Arch: aLE 10 8.77  0.51 ††,∧ 2.70  0.48 5.73  0.43 42.50  2.81 14.70  2.65 56.40  4.74 ∧∧ 1.50  0.08 1.31  0.08 1.48  0.08
Orexin/Arch: aHE 5 10.80  0.98 ,† †† 3.33  0.23 7.06  0.43 56.00  3.17 † 21.60  3.17 76.60  4.50** 1.37  0.10 1.14  0.12 1.31  0.07
Two-way ANOVA F(6,48)  9.69; p  0.0001 F(6,48)  4.42; p  0.0012 F(6,48)  1.82; p  0.114
Cataplexy
Orexin/Ataxin-3 5 0.00  0.00 0.44  0.25 0.22  0.12 0.00  0.00 2.40  1.21 2.40  1.21 — 1.13  0.27 1.13  0.27
*p  0.05; **p  0.01; ***p  0.001 versus WT.
†p  0.05; ††p  0.01; †††p  0.001 versus ATAX.
∧p  0.05; ∧∧p  0.01 versus aHE.
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treatment  time interaction: F(2,18)  42.13; p  0.0001; Fig.
5-1 Bi, available at https://doi.org/10.1523/JNEUROSCI.0311-
19.2019.f5-1 vs Fig. 5–1Ai, available at https://doi.org/10.1523/
JNEUROSCI.0311-19.2019.f5-1). In comparison, Tb increased
during the CCA in all phases (Fig. 5-1Bii, available at https://
doi.org/10.1523/JNEUROSCI.0311-19.2019.f5-1) with signifi-
cant treatment  time interactions for WT (two-way repeated-
measures ANOVA, F(2,14)  14.29; p  0.0001), aLE (two-way
repeated-measures ANOVA, F(2,18)  18.79; p  0.0001), and
aHE (two-way repeated-measures ANOVA, F(2,8)  14.88; p 
0.0020) mice.
Spectral analysis of baseline wake, NREM, and REM states
during the active (ZT12-ZT23) and inactive phases (ZT0-ZT11)
revealed nominally significant (Bonferroni-corrected threshold
  0.02) differences in the frequency bands in orexin/Arch mice
(Fig. 5C), despite relatively normal sleep–wake architecture.
These differences were more prominent in total spectral power
during wake across the 24 h baseline period (two-way repeated-
Figure 6. Sleep homeostasis parameters are normal in orexin/Arch mice. A, Percentage of wake, NREM, and REM sleep during a 4 h SD period initiated at ZT0 (blue shading) and the subsequent
recovery period from ZT4 to ZT12. B, The latencies to NREM and REM sleep were significantly shorter in orexin/Arch mice under baseline conditions, but all genotypes had similar latencies after 4 h
SD. C, After 4 h SD, all mice increased EEG delta power during NREM sleep, indicating comparable sleep homeostasis across genotypes. D, An mMSLT, comprised of five 20 min SD sessions interspersed
with five 20 min “nap” opportunities, was initiated at ZT3 to assess sleepiness of each genotype. E, Latencies to NREM and REM sleep for all 4 genotypes during each “nap” opportunity of the mMSLT
indicated that ATAX mice had significantly shorter REM latencies during the third and fourth nap opportunities. F, After initiation of access to chocolate at ZT12, total FI (i.e., consumption of chocolate
and chow) was measured over the subsequent 4 h. Orexin/Arch mice had food preference and consumption levels comparable with WT and ATAX mice. Mice were then killed at ZT16, and assessment
of c-FOS expression in Hcrt/orexin neurons indicated that orexin/Arch mice had levels of cFOS in Hcrt/orexin neurons comparable with WT mice, and that cFOS expression was not specific to
Hcrt/orexin neurons within the LHA. Values are mean  SEM. *p  0.05, **p  0.01, ***p  0.001 as in legends to Figures 4 and 5.
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measures ANOVA, significant genotype  spectral band interac-
tions for wake: F(12,96)  3.05; p  0.001). There were also
significant genotype  spectral band interactions for NREM
(F(12,96)  2.35; p  0.01), whereas REM genotype  spectral
band interaction did not reach significance (F(12,96)  0.027).
Compared with WT mice in the wake state, aLE mice had in-
creased alpha power and aHE had increased beta power. There
was a trend for increased beta power in aHE during NREM and
delta power in REM compared with WT (both p  0.03). In
contrast, ATAX mice did not differ from WT mice in any EEG
spectral parameter during either phase or across the 24 h period.
Sleep homeostasis is intact in orexin/Arch transgenic mice
Homeostatic sleep regulation was evaluated by analyzing the re-
sponse to 4 h SD initiated at ZT0 (Fig. 6A). During the 4 h SD, all
mice exhibited increased activity (Fig. 5-1Ci, available at https://
doi.org/10.1523/JNEUROSCI.0311-19.2019.f5-1). A genotype 
time interaction was evident in the hourly Tb data (two-way
repeated-measures ANOVA, F(69,552)  1.40; p  0.02; Fig.
5-1Cii, left, available at https://doi.org/10.1523/JNEUROSCI.
0311-19.2019.f5-1) that was not significant when the data were
collapsed into bins corresponding to the light and dark phases
(two-way repeated-measures ANOVA, F(6,48)  1.98; p  0.089;
Fig. 5-1Cii, right, available at https://doi.org/10.1523/JNEUROSCI.
0311-19.2019.f5-1).
ATAX mice were the most difficult of the 4 strains to keep
awake across the 4 h SD period (Fig. 6A). During the recovery
sleep opportunity period (ZT5-ZT12), all genotypes exhibited a
similar distribution of sleep–wake. Under baseline conditions,
the latency to NREM (measured from light onset) was consis-
tently shorter in orexin/Arch mice compared with WTs (Fig. 6B),
and both orexin/Arch and ATAX mice had significantly faster
REM sleep onsets than WT mice. Following SD, all genotypes
had a reduced NREM and REM sleep latency (measured from
cessation of SD) that did not differ across strains. NRD was
elevated during recovery sleep in all strains (Fig. 6C), suggest-
ing that the sleep homeostat is unaltered in either orexin/Arch
or ATAX mice.
To assess sleep propensity, we used an mMSLT that began at
ZT3 to further challenge the sleep homeostat (Fig. 6D). We found
no significant difference across genotypes in wake or NREM
states during the five 20 min nap opportunities. NREM latency
was comparable across genotypes, except for the first nap op-
portunity, during which aHE mice took longer to enter NREM
(Fig. 6E). REM sleep latencies were comparable between WT
and orexin/Arch mice, but ATAX mice tended to have shorter
latencies, which were significant in nap opportunities 3 and 4
(Fig. 6E).
Food preference and c-FOS expression across genotypes
To determine whether aberrant Hcrt/orexin neuron function af-
fected food preference between chow and chocolate, we per-
formed a final CCA in which mice were killed 4 h after chocolate
presentation (Oishi et al., 2013). We found that all genotypes
preferentially ate chocolate over chow (Fig. 6F) and only aLE
mice ate significantly more chow than WT (two-way ANOVA,
p  0.03). Overall, the genotypes exhibited a similar range of total
FI and did not significantly differ from each other.
After 4 h exposure to chocolate from ZT12-ZT16, we assessed
cellular activation in the LHA by measuring cFOS- and orexin-
IR. The number of Hcrt/orexin neurons counted was similar
across WT and orexin/Arch mice (WT: 90.23  9.68 cells; aLE:
83.93  1.04 cells; aHE: 83.06  3.63 cells) and largely absent in
the mouse model of NT1 (ATAX: 2.5  0.51 cells). The percent-
age of Hcrt/orexin neurons expressing c-FOS was comparable
between WT (38.48  4.4%, n  8) and orexin/Arch mice (aLE:
44.77  3.4%, n  10; aHE: 44.90  4.7%, n  5). Total cFOS-IR
indicated a more general activation of LHA neurons since the
percentage of orexin/Fos neurons only accounted for a pro-
portion of the total c-FOS-expressing cells in the LHA (WT:
44.63  4.18%, aLE: 44.91  2.45%, aHE: 49.22  4.49%).
Discussion
Optogenetics has been a useful tool to further our understanding
of the roles of different neurotransmitter systems in sleep–wake
control (Jego et al., 2013; Konadhode et al., 2013; Irmak and de
Lecea, 2014; Tsunematsu et al., 2014; Van Dort et al., 2015; Xu et
al., 2015), including Hcrt/orexin (Adamantidis et al., 2007;
Carter et al., 2009, 2012; Tsunematsu et al., 2011, 2013). In the
present study, we used the light-sensitive Arch protein, which
inhibits neurons through a proton pump. We found that photoil-
lumination of Hcrt/orexin cells expressing Arch in transgenic
orexin/Arch mice could induce sleep with short latency but that
the efficacy of sleep induction was dependent on time of day and
the degree of transgene expression. Furthermore, high Arch ex-
pression levels affected Hcrt neuron excitability and physiology,
including energy metabolism, locomotor activity, REM sleep
amount, and EEG spectra.
Photoillumination-induced sleep in Orexin/Arch mice
In studies in which the light-sensitive chloride channel halorho-
dopsin (Tsunematsu et al., 2011) or the proton pump ArchT
(Tsunematsu et al., 2013) was expressed in Hcrt/orexin neurons,
brief (1 min) photoillumination induced NREM sleep with short
latency only at certain times of day. Here, 1 min photoillumina-
tion of Arch-expressing Hcrt neurons induced NREM only dur-
ing the light phase (Fig. 2C), supporting the concept of the Hcrt
system as a “wake-maintaining” rather than a “wake-promoting”
system. Narcoleptic patients and their animal counterparts that
lack Hcrt neurons or have compromised Hcrt signaling are able
to awaken but are less able to sustain long periods of wakefulness.
Photic inhibition of Arch-containing Hcrt neurons during the
light phase reduces Hcrt neural activity and creates conditions
that are permissive for sleep to occur when sleep drive is high,
resulting in shorter sleep onset latency. Conversely, 1 min pho-
toillumination during the dark phase was ineffective because
other arousal systems are activated at that time (Suzuki et al.,
2013).
In contrast, longer 1 h photoillumination produced sleep only
during the dark phase (Fig. 2) and not during the light phase (Fig.
2), which may seem paradoxical. However, since there is rela-
tively little sleep early in the dark phase, even a small amount of
sleep induced through inhibition of Hcrt neural activity can re-
sult in a significant change in sleep amounts. Conversely, a 1 h
photoillumination during the light phase fails to produce signif-
icant effects due to a “ceiling effect” since this is the major sleep
period for mice and the time of day when Hcrt/orexin levels are
minimal.
Novel observations in Orexin/Ataxin-3 (ATAX) mice
Because loss of Hcrt neurons in ATAX mice provides face validity
with NT1, this model has been used for pharmacological studies
(Xie et al., 2008; Hara et al., 2009; Okuro et al., 2010; Black et al.,
2013, 2014, 2017b; Sagawa et al., 2016). The original description
of this strain described behavioral arrests resembling cataplexy,
disrupted sleep architecture, reduced wake bout durations in
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both light and dark phases, more REM sleep in the dark phase due
to longer bouts, reduced LMA, and late-onset obesity despite
lower food consumption than nontransgenic littermates (Hara et
al., 2001). We confirmed virtually all of these features, including
cataplexy (Fig. 5Aiv), reduced wake bout durations (Fig. 5Ai) and
activity (Fig. 4Aii) during the dark phase, and disrupted sleep
architecture (increased numbers of wake and NREM bouts dur-
ing the dark phase and across the 24 h period; Fig. 5A), and
increased weight gain relative to WT mice (Fig. 4B, inset) despite
reduced FI (Fig. 4Aii). In addition, we find that ATAX mice have
reduced RER during the dark phase. These results confirm that
ATAX mice replicate the metabolic and arousal state abnormali-
ties characteristic of NT1.
The present study also extends characterization of sleep–wake
abnormalities in ATAX mice. Although these mice entrained nor-
mally to an LD cycle, they had a longer circadian period than WT
mice or either orexin/Arch subgroup (Fig. 4E), ATAX mice drifted
very little from 24 h (tau  23.90  0.06 h). Cataplexy in ATAX
mice was greatly exacerbated in the CCA (Fig. 5Biv vs Fig. 5Aiv).
On the other hand, the EEG spectra (Fig. 5C) and homeostatic
response to 4 h SD (Fig. 6A) were unchanged in ATAX mice
relative to WT. Sleep homeostasis has been reported as normal
(Dantz et al., 1994) or enhanced in narcoleptic patients (Tafti et
al., 1992) and other narcoleptic models (Mochizuki et al., 2004;
Vassalli and Franken, 2017). ATAX mice had faster REM sleep
onset in 4 of the 5 nap opportunities during the mMSLT than the
other strains tested, further validating this strain as a model of
NT1.
aHE Orexin/Arch mice: a possible model of narcolepsy Type
2 (NT2)?
ATAX and orexin-tTA;TetO-DTA mice (Tabuchi et al., 2014) are
accepted NT1 models because of their Hcrt/orexin neuron loss,
cataplexy, disrupted sleep architecture, and metabolic abnormal-
ities. Short latency REM onsets during the mMSLT resemble the
sleep onset REM periods that are diagnostic of human NT1,
which is also characterized by low CSF Hcrt-1/orexin-A levels. In
contrast, Type 2 narcolepsy (NT2) shares some NT1 features,
such as EDS and sleep onset REM periods, but without cataplexy
and usually with normal CSF Hcrt-1/orexin-A levels (Scammell,
2015; Black et al., 2017a; Bassetti et al., 2019; Szabo et al., 2019). A
subset (10%–20%) of NT2 patients may progress to NT1 over
their lifetime, but the large majority of NT2 patients will not;
nonprogressing NT2 patients are thought to have a distinct dis-
order that may involve dysfunction of the Hcrt system without
the massive cell loss found in NT1 (Bassetti et al., 2019; Szabo et
al., 2019).
The abnormal Hcrt neuron properties in aHE mice (Fig. 3)
raise the question whether this strain could be a useful NT2
model. aHE mice exhibited obesity as well as lower RER values
during the light phase but greater RER during the dark phase than
age-matched WT mice (Fig. 4Aii). Low RER values during the
light phase have also been reported in aged Hcrt/orexin ligand
KO mice (Ramanathan and Siegel, 2014). The increased RER in
the dark phase was present in both orexin/Arch subgroups, but
ATAX mice had the reverse pattern. Activity measured in the
CLAMS system was elevated in the dark phase in both orexin/
Arch strains (Fig. 4Aii) but, when provided access to a running
wheel, aHE mice ran less than any other strain (Fig. 4E; Table 2).
Although many factors could contribute to reduced activity,
other mouse models with compromised Hcrt signaling are less
willing to work for a positive reward (McGregor et al., 2011),
the emotional valence that is associated with running activity.
aHE mice also had more REM bouts than other strains across
the 24 h period (Fig. 5Aiii) and a shorter REM latency under
baseline conditions (Fig. 6B) but not on the mMSLT (Fig. 6E).
The aHE phenotype was distinct from ATAX mice as aHE mice
showed 24 h FI (Fig. 4Aii), circadian periodicity (Fig. 4E), and
REM latency on mMSLT that was equivalent to WT mice and,
like NT2 patients, they lacked cataplexy (Fig. 5Aiv). Of all the
strains examined, aHE mice consistently showed the most ab-
normal EEG spectra, with increased beta power in wake and
further trends for altered spectra bands in NREM and REM
(Fig. 5C).
For aHE mice to be considered as a model for NT2, key fea-
tures, such as the absence of cataplexy, reduced sleep latency,
increased sleep fragmentation, EDS, SOREM, and normal levels
of hypocretin/orexin expression, should be present. We found
that aHE mice lack cataplexy (Fig. 5Aiv), have increased REM
sleep (Fig. 5Aiii), reduced sleep latency under basal conditions
(Fig. 6B), and normal orexin cell counts. However, aHE mice did
not present sleep–wake fragmentation, nor did we observe EDS
or SOREM during the mMSLT evaluation. Thus, although aHE
mice share some, but not all, of the characteristics of NT2, they
may be the best available model to study this disorder.
Limitations of viral versus transgenic approaches
to optogenetics
Previous optogenetic studies have either used viral-mediated or
transgenic approaches to introduce light-sensitive proteins into
the Hcrt neurons. Appropriate expression of light-sensitive pro-
teins via viral delivery depends upon the accuracy of stereotaxic
injections, efficacy of viral penetration into the relevant neuronal
population, and subsequent gene transcription and translation of
the protein. The efficiency of this approach has been greatly aided
by Cre-dependent viruses and transgenic mouse strains that ex-
press Cre recombinase. In contrast, transgenic mice can provide
stable expression, which may enable more reproducible results,
although ectopic expression can be problematic. The present
study demonstrates another limitation of transgenic lines: the
phenotype observed may be due to disruption of normal cellular
function due to the level of opsin expression. In the present study,
the phenotypic characterization of orexin/Arch mice at the cellu-
lar and organismal levels documented as many differences be-
tween aLE and aHE mice as between either subgroup and WT
mice, underscoring the need for thorough characterization of
transgenic models. Such extensive phenotyping may avoid inap-
propriate attribution of a gain or loss of function to an interven-
tion, such as optogenetic stimulation, which may indeed be due
to transgene expression-dependent modification of cellular
properties and concomitant downstream effects.
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